Cartesian Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Cartesian Therapeutics, Inc. (RNAC) reported Net Income (Loss) Available to Common Stockholders, Diluted of $13.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- Cartesian Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $13.72M, a 3.48% increase year-over-year.
- Cartesian Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $13.26M, a 37.70% increase year-over-year.
- Cartesian Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-06-30 was $9.63M.
- Cartesian Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-03-31 was -$56.82M.
- Cartesian Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$130.30M.
- Cartesian Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$77.87M.
- Cartesian Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$257.26M, a 1874.57% decline from fiscal 2022.
- Cartesian Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was $14.50M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.72M 10-Q · filed 2026-08-06 | -$23.41M 10-Q · filed 2026-08-06 | ||
| 2025-12-31 | -$130.30M 10-K · filed 2026-03-09 | |||
| 2025-06-30 | $13.26M 10-Q · filed 2026-08-06 | -$1.82M 10-Q · filed 2026-08-06 | ||
| 2024-12-31 | -$77.87M 10-K · filed 2026-03-09 | |||
| 2024-06-30 | $9.63M 10-Q · filed 2025-08-07 | -$42.99M 10-Q · filed 2025-08-07 | -$262.40M derived: sum of 3 quarters · filed 2025-08-07 | -$271.41M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$56.82M 10-Q · filed 2024-05-08 | -$272.03M derived: sum of 2 quarters · filed 2025-03-13 | -$281.03M derived: sum of 3 quarters · filed 2025-03-13 | -$292.42M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | -$215.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$224.21M derived: sum of 2 quarters · filed 2025-03-13 | -$235.60M derived: sum of 3 quarters · filed 2025-03-13 | -$257.26M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$9.00M 10-Q · filed 2023-11-13 | -$20.39M derived: sum of 2 quarters · filed 2024-08-08 | -$42.05M 10-Q · filed 2023-11-13 | -$49.71M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | -$11.39M 10-Q · filed 2024-08-08 | -$33.05M 10-Q · filed 2024-08-08 | -$40.71M derived: sum of 3 quarters · filed 2024-08-08 | -$48.60M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$21.66M 10-Q · filed 2024-05-08 | -$29.32M derived: sum of 2 quarters · filed 2024-05-08 | -$37.22M derived: sum of 3 quarters · filed 2024-05-08 | -$28.61M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$15.55M derived: sum of 2 quarters · filed 2024-03-07 | -$6.95M derived: sum of 3 quarters · filed 2024-03-07 | $14.50M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$7.89M 10-Q · filed 2023-11-13 | $708.00K derived: sum of 2 quarters · filed 2023-11-13 | $22.16M 10-Q · filed 2023-11-13 | $23.21M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $8.60M 10-Q · filed 2023-08-17 | $23.51M 10-Q · filed 2023-08-17 | $31.10M derived: sum of 3 quarters · filed 2024-03-07 | $13.21M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $10.26M 10-Q · filed 2023-05-04 | $22.50M derived: sum of 2 quarters · filed 2024-03-07 | $4.61M derived: sum of 3 quarters · filed 2024-03-07 | $4.35M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $12.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$5.66M derived: sum of 2 quarters · filed 2024-03-07 | -$5.91M derived: sum of 3 quarters · filed 2024-03-07 | -$25.69M 10-K · filed 2024-03-07 |
| 2021-09-30 | -$17.89M 10-Q · filed 2022-11-03 | -$18.15M derived: sum of 2 quarters · filed 2022-11-03 | -$37.93M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$255.00K 10-Q · filed 2022-08-08 | -$20.03M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$24.60M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |